Clinical Trial Update: Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and immunogenicity of TBC-M4, an MVA-based HIV vaccine, administered alone or in a prime-boost regimen with the ADVAX DNA HI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ADVAX DNA HIV Vaccine (DNA vaccine for HIV)
• TBC-M4

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: HIV Infections | Phase 1 | Status: COMPLETED